The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis - GBI Research Reports

The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis - GBI Research Reports
The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Published Dec 31, 2009
148 pages — Published Dec 31, 2009
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

SummaryGBI Research, the leading business intelligence provider, has released its latest research 'The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.' The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global metabolic disorder therapeutics market. The report analyzes the markets for metabolic disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.ScopeThe scope of this report includes:- Annualized market data for the metabolic disorder therapeutics market from 2000 to 2008, forecast forward to 2015- Analysis of the leading therapeutic segments including diabetes and obesity.- Analysis of the metabolic disorder therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan - Market characterization of the metabolic disorder therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns - Key drivers and barriers that have a significant impact on the market - Coverage of pipeline molecules in various phases of drug development - Competitive benchmarking of leading companies. The key companies studied in this report are Novo Nordisk A/S, Eli Lilly, Takeda Pharmaceuticals, Sanofi-aventis and GlaxoSmithKline.- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global metabolic disorder therapeutics marketReasons to buyThe report will enhance your decision making capability. It will allow you to- Align product portfolio to the markets with high growth potential- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth - Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety- Develop key strategic initiatives by understanding key focus areas of leading companies - Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

  
Source:
Document ID
GBIHC023MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents49
1.1 List of Tables72
1.2 List of Figures94
2 Global Metabolic Disorders Therapeutics Market: Introduction132
2.1 GBI Research Report Guidance132
3 Global Metabolic Disorders Therapeutics Market: Market Overview1515
3.1 Introduction151
3.2 Revenue Forecasts for the Global Metabolic Disorders Therapeutics Market151
3.2.1 Sales Value151
3.2.2 Sales Volume161
3.2.3 Annual Cost of Therapy172
3.2.4 Treatment Usage Patterns191
3.2.4.1 Diseased Population201
3.2.4.2 Treatment Seeking Population201
3.2.4.3 Diagnosed Population211
3.2.4.4 Prescription Population221
3.2.5 Generics Share in the Global Metabolic Disorders Therapeutics Market232
SWOT Analysis251
3.3.1 Strength251
3.3.1.1 Significant Growth in Metabolic Disorders Diseased Population is the Greatest Strength to the Global Metabolic Disorders Market251
3.3.1.2 Drug Treatment is One of the Key Treatment Options Available for Diabetes Patients251
3.3.1.3 Metabolic Disorders R&D Pipeline though is Weak, a Few First-in-class Drugs in Late-stage Development will Bolster the Future Growth of the Market251
3.3.2 Weakness261
3.3.2.1 Poor Patient Compliance of Insulin Injections, Oral Antidiabetic Drugs Such as Avandia, and Anti-obesity Drugs such as Meredia Proved Detrimental to the Growth of Metabolic Disorders Market261
3.3.3 Opportunity261
3.3.3.1 High Unmet Needs Still Exist in the Metabolic Disorders Market and Drugs with Modest Efficacy and High Safety Profile will have the Opportunity to Become Future Potential Blockbuster 261
3.3.3.2 Disease Awareness Campaigns Reinforce the Growth of Diagnosed Population Percentage261
3.3.4 Threat261
3.3.4.1 Recent Findings of Anti-diabetic Drugs Potential Side-effects Forced FDA to Tighten Drug Approvals261
3.3.4.2 Unfavorable Reimbursement Coverage in Major Countries Poses Grave Threat to the Growth of Metabolic Disorders Market261
3.4 Metabolic Disorders Therapeutics Market Drivers271
3.4.1 High Unmet Needs in the Obesity Market Create a Huge Market Opportunity for Future Potential Blockbusters271
3.4.2 Drastic Raise in Metabolic Disorders Diseased Population in the Developed Countries271
3.4.3 Technological Advances in the Diabetic Therapies Market are expected to Enhance Patient Acceptability and Therefore Patient-base281
3.4.4 Sedentary Life Styles and Increased Consumption of Fat-rich Products Driving the Growth of Metabolic Disorders Diseased Population281
3.5 Metabolic Disorders Therapeutics Market Restraints281
3.5.1 Severe Side-effects Associated with Metabolic Disorder Drugs are Proving Detrimental to the Growth of the Market281
3.5.2 Lack of Proper Reimbursement Coverage in Countries such as Germany and France Restraining the Growth of the Market291
3.5.3 Generics Pose Significant Threat to the Global Metabolic Disorders Therapeutics Market291
4 Global Metabolic Disorders Therapeutics Market: Therapeutic Landscape3031
4.1 Diabetes Market301
4.1.1 Introduction301
4.1.2 Unmet Needs301
4.1.2.1 Some of the Anti-diabetic Drugs Carry Cardiovascular Risks301
4.1.2.2 Insulin Delivery Systems Carry Poor Patients Compliance301
Use of Insulin Analogues might trigger Carcinogenic Effects in the Body311
4.1.3 Sales Value311
4.1.4 Sales Volume321
4.1.5 Annual Cost of Therapy332
Treatment Usage Patterns351
4.1.6.1 Diseased Population361
4.1.6.2 Treatment Seeking Population371
4.1.6.3 Diagnosed Population371
4.1.6.4 Prescription Population 381
4.1.7 Geographical Segmentation393
4.1.8 Generics Share in the Global Diabetes Market423
Drivers of Diabetes Market451
4.1.9.1 Ageing, Deskbound Lifestyles and Increased Consumption of Junk Food are the Driving Forces of Metabolic Disorders Prevalence451
4.1.9.2 Diabetes on the Rise in U.S451
4.1.9.3 New First-in-class Drugs in Early Stage Clinical development 451
4.1.9.4 Diabetes Awareness Campaigns Directed at Educating Patients, are Driving the Treatment Seeking Population461
4.1.10 Restraints of Diabetes Market461
4.1.10.1 Cardiovascular Side Effects Affecting Prescription Sales of Diabetes Drugs461
4.1.10.2 Patent Expiry of Blockbusters such as Actos, Starlix and Avandia is Expected to Restrain the Growth of the Global Diabetes Market461
4.2 Obesity Market461
4.2.1 Introduction461
4.2.2 Sales Value462
4.2.3 Sales Volume481
4.2.4 Annual Cost of Therapy491
4.2.5 Treatment Usage Patterns501
4.2.5.1 Diseased Population511
4.2.5.2 Treatment Seeking Population521
4.2.5.3 Diagnosed Population521
4.2.5.4 Prescription Population 531
4.2.6 Geographical Segmentation543
4.2.7 Generics Share in the Global Obesity Market572
4.2.8 Drivers of Obesity Market591
4.2.8.1 High Unmet Needs Exist in the Obesity Market and Therefore, Any Drug That Can Manage to Pass through FDA Approval will be a Blockbuster591
4.2.8.2 Rapidly Growing Obesity Population in Major Countries Driving the Growth of the Anti-Obesity Drugs Market601
4.2.9 Restraints of Obesity Market601
4.2.9.1 Side-effects associated with anti-obesity drugs are very high601
4.2.9.2 Refusal by Healthcare Authorities to Grant Reimbursement to Anti-obesity Drugs has Impeded Growth601
4.2.9.3 Availability of other Non-therapeutic Treatments such as herbal treatment and weight-loss treatments detrimental to the growth of the global obesity market601
5 Global Metabolic Disorders Therapeutics Market: Geographical Landscape6125
5.1 Geographical Break-up613
5.2 The US641
5.2.1 Sales Value641
5.2.2 Sales Volume651
5.2.3 Annual Cost of Therapy661
5.2.4 Treatment Usage Patterns671
5.2.4.1 Diseased Population681
5.2.4.2 Treatment Seeking Population681
5.2.4.3 Diagnosed Population691
5.2.4.4 Prescription Population 701
5.3 Top Five Countries in Europe711
5.3.1 Sales Value711
5.3.2 Sales Volume721
5.3.3 Annual Cost of Therapy731
5.3.4 Treatment Usage Patterns741
5.3.4.1 Diseased Population751
5.3.4.2 Treatment Seeking Population761
5.3.4.3 Diagnosed Population771
5.3.4.4 Prescription Population 781
5.4 Japan791
5.4.1 Sales Value791
5.4.2 Sales Volume801
5.4.3 Annual Cost of Therapy811
5.4.4 Treatment Usage Patterns821
Diseased Population831
5.4.4.2 Treatment Seeking Population831
5.4.4.3 Diagnosed Population841
5.4.4.4 Prescription Population 851
6 Global Metabolic Disorders Therapeutics Market: Pipeline Analysis8614
6.1 Introduction861
6.1.1 Research and Development Pipeline - Diabetes 872
6.1.1.1 Type 1 Diabetes892
6.1.1.2 Type 2 Diabetes911
6.1.2 Research and Development Pipeline - Obesity913
6.2 R&D Trends941
6.2.1 New Promising Treatments for Diabetic Retinopathy941
6.2.2 Identifying Biomarkers will Mark an Important Step in Metabolic Disorders R&D941
6.2.3 Combination Drugs is an Important Part of Diabetes and Obesity Pipeline941
6.2.4 First-in-class Insulin Pills (Oral Delivery) in Development941
6.3 New Drug Insulin Delivery Systems951
6.3.1 Altea Therapeutics Transdermal Passport System951
6.3.1.1 Introduction951
6.3.1.2 Mode of Delivery951
6.3.1.3 Impact951
6.3.2 Technosphere/Insulin Mimics Early Post-Prandial Insulin Release951
6.3.2.1 Introduction951
6.3.2.2 Mode of Delivery951
6.3.2.3 Impact 961
6.4 Profiles of Key Late-Stage Drugs in the Diabetes Market961
6.4.1 Teplizumab961
6.4.1.1 Introduction961
6.4.1.2 Mechanism of Action961
6.4.1.3 Clinical Trial Management961
6.4.2 Oral-Lyn961
6.4.2.1 Introduction961
6.4.2.2 Mechanism of Action971
6.4.2.3 Clinical Trial Management971
6.4.3 Liraglutide for Diabetes971
6.4.3.1 Introduction971
6.4.3.2 Mechanism of Action971
6.4.3.3 Clinical Trial Management971
6.5 Profiles of Key Late-Stage Drugs in the Obesity Market981
6.5.1 Lorcaserin981
6.5.1.1 Introduction981
6.5.1.2 Mechanism of Action981
6.5.1.3 Clinical Trial Management981
6.5.2 Contrave991
6.5.2.1 Introduction991
6.5.2.2 Mechanism of Action991
6.5.2.3 Clinical Trial Management991
6.5.3 Liraglutide for Obesity991
6.5.3.1 Introduction991
6.5.3.2 Mechanism of Action991
6.5.3.3 Clinical Trial Management991
7 Global Metabolic Disorders Therapeutics Market: Competitive Landscape10029
7.1 Diabetes Market Overview1002
7.2 Market Share Analysis: Diabetes Therapeutics1021
7.3 Obesity Market Overview1032
7.4 Market Share Analysis: Obesity Therapeutics1051
7.5 Competitive Profiling1061
7.5.1 Diabetes Therapeutics Market1061
7.5.2 Obesity Therapeutics Market1071
7.5.3 Human Insulin Products and Oral Antidiabetic Drugs Like Actos Group (Actos and Actoplus met) and Lantus Have Led Market Growth 1081
7.5.4 Novo Nordisk1091
7.5.4.1 Product Portfolio1101
7.5.4.2 Product Pipeline1111
7.5.5 Sanofi-aventis1112
7.5.5.1 Product Portfolio1131
7.5.5.2 Product Pipeline1141
7.5.6 Takeda1141
7.5.6.1 Product Portfolio1151
7.5.6.2 Product Pipeline1151
7.5.7 Eli Lilly1151
7.5.7.1 Product Portfolio1161
7.5.7.2 Product Pipeline1171
7.5.8 GlaxoSmithKline (GSK)1182
7.5.8.1 Product Portfolio1201
7.5.8.2 Product Pipeline1211
7.5.9 Merck &Co Inc1211
7.5.9.1 Product Portfolio1221
7.5.9.2 Product Pipeline1231
7.5.10 Amylin Pharmaceuticals1231
7.5.10.1 Product Portfolio1241
7.5.10.2 Product Pipeline1251
7.5.11 Roche1251
7.5.11.1 Product Portfolio1261
7.5.11.2 Pipeline Product1261
7.5.12 Abbott1271
7.5.12.1 Product Portfolio1281
7.5.12.2 Product Pipeline1281
8 Global Metabolic Disorders Therapeutics Market: Strategic Consolidations12914
8.1 Overview1291
8.1.1 Ligand Pharmaceuticals Acquired Metabasis Therapeutics in October 20091301
8.1.2 CombinatoRx, Inc. Acquired Neuromed Pharmaceuticals, Inc. in August 20091311
8.1.3 Mylan Laboratories Acquired Matrix Laboratories Limited in March 20091311
8.1.4 Pfizer Acquired Wyeth in January 20091311
8.1.5 Wyeth Acquired Thiakis Ltd. in December 20081311
8.1.6 Bellus Health Inc. Acquired Innodia Inc in July 20081311
8.1.7 GlaxoSmithKline Acquired Sirtris Pharmaceuticals in April 20081311
8.1.8 Point Therapeutics and Dara Biosciences Merged in February 20081321
8.1.9 Teva Pharmaceutical Industries Acquired Cogenesys, Inc. in January 20081321
8.2 R&D Licensing Agreements 1321
8.2.1 Deals by Indication1321
8.2.2 Deals by Phase1331
8.2.3 Deals by Geography1331
8.2.4 Deals by Licensing Type1341
8.2.5 Deals by Value ($)1351
8.2.6 Preclinical1361
Verva FGFR Portfolio 1361
8.2.6.2 Debio 09301361
8.2.6.3 DGAT1 Program1371
8.2.6.4 Organix 5-HT2C Agonists1371
8.2.6.5 Telik Insulin Receptor Activators1371
8.2.6.6 MT 39 series1371
8.2.6.7 MKG021371
8.2.6.8 Gal/Merck Obesity &Diabetes Program1371
8.2.6.9 Glucagon Targeted Therapies1371
8.2.7 Phase I1381
Exenatide Transdermal Formulation1381
8.2.8 Phase II1381
8.2.8.1 Davalintide and Pramlintide1381
8.2.8.2 PN20341381
BHT-30211391
8.2.8.4 SK-04031391
8.2.8.5 TT-2231391
8.2.9 Phase III1391
8.2.9.1 Dutogliptin tartrate (PHX1149)1401
8.2.9.2 Oral-lyn with Dongsung Pharmaceutical1401
8.2.9.3 Oral-lyn with Scigen Limited1401
8.2.10 Approved1401
Galvus and Eucreas1411
8.2.10.2 SciLin1411
8.2.10.3 Gliconorm1411
8.2.10.4 Glipizide + Metformin HCl1411
8.2.10.5 Januvia1411
8.2.10.6 Glumetza1421
9 Global Metabolic Disorders therapeutics Market: Appendix1436
9.1 Market Definitions1431
9.2 Abbreviations1431
9.3 Research Methodology1444
9.3.1 Coverage 1441
9.3.2 Secondary Research1451
9.3.3 Primary Research1451
9.3.4 Forecasts1451
9.3.4.1 Epidemiology-based Forecasting1452
9.3.5 Expert Panel Validation1471

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis" Dec 31, 2009. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Metabolic-Disorder-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis-2115-14>
  
APA:
GBI Research Reports. (2009). The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis Dec 31, 2009. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/The-Future-of-Metabolic-Disorder-Therapeutics-Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis-2115-14>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.